Uncovering pathogenic anti-bacterial defense mechanisms to identify novel targets for prevention of T1D
Uncovering pathogenic anti-bacterial defense mechanisms to identify novel targets for prevention of T1D
批准号:
10207399
负责人:
Nora E Sarvetnick
金额:
$57.94万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-07-01 至 2024-06-30
关键词:
AdolescentAnimal ModelAnimalsAnti-Bacterial AgentsAntibacterial ResponseAntigensAreaAutoimmune DiseasesAutoimmunityB-LymphocytesBacteriaCellsClinicalDataDefense MechanismsDevelopmentDiabetes MellitusDiffuseDiseaseDuodenumExperimental ModelsExposure toExtravasationGoalsHumanHyperglycemiaImmuneImmune systemImmunityImmunoglobulin AInflammationInflammation MediatorsInsulin-Dependent Diabetes MellitusInterleukin-17IntestinesIslets of LangerhansLeaky GutLinkMucosal Immune ResponsesMusNeutrophil InfiltrationOnset of illnessPancreasPathogenesisPathogenicityPathologicPathway interactionsPreclinical TestingPreventionPrevention strategyResearchRoleSecretory Immunoglobulin AT-LymphocyteTestingTherapeutic Interventionbasechemokinecooperative studydesigndiabetes controldisorder preventiondysbiosisexperimental studyimmune activationin vivoinsulin dependent diabetes mellitus onsetinsulitisinterestisletmicrobiomemouse modelnovelnovel therapeutic interventionpreventpreventive interventionresponsetherapeutic evaluationtranscriptome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
While contemporary research has shown Type 1 diabetes (T1D) is associated with intestinal
dysbacteriosis and leakage, it is not known whether these factors cause the disease.
Establishing a causative link between the onset and progression of T1D and dysbacteriosis is
critical for developing effective prevention strategies. The overarching hypothesis of this
application is that T1D is preceded by pancreatic bacterial exposure, which promotes an anti-
bacterial response, pancreatic inflammation, insulitis, and autoimmunity. This hypothesis was
formulated based on our preliminary data demonstrating: 1) heightened anti-bacterial
responses in juvenile T1D; 2) pathologic responses by islets to bacteria overrepresented in the
T1D microbiome; 3) pancreatic inflammation and insulitis in a mouse model of experimental
leakage of bacteria into the pancreas; and 4) blockade of the anti-bacterial response protects
islets from insulitis. In aim 1 we will determine whether human T1D development is
preceded by a cellular and humoral anti-bacterial response and establish an association
with the duodenal microbiome. We will test whether bacteria-responsive MAIT cells are
activated before clinical disease develops and determine if they are differentially activated by
overrepresented bacteria. Next, we will discover whether the increased anti-bacterial IgA
response in T1D is directed at overrepresented bacteria. We will profile the duodenal
microbiome and determine if it is associated with these defense mechanisms. In aim 2 we will
ascertain whether pancreatic exposure to bacteria leads to immune activation, insulitis,
and hyperglycemia. We will determine whether pancreatic islets show distinct responses to
specific T1D-associated bacteria including R. gnavus, B. Dorei, and S. infantarius. Lastly, we
will interrogate the mediators of inflammation and insulitis following pancreatic exposure to
overrepresented bacterial species and test strategies to block the response. To accomplish this
task, we have established a novel mouse animal of intestinal dysbiosis and leakage to
test therapeutic interventions. The proposed experiments will identify pathogenic
mechanisms that link intestinal dysbiosis and leakage to T1D uncovering new targets for
prevention. These targets will undergo preclinical testing in this application. This submission is
responsive to the U01 Cooperative Study Group for Autoimmune Disease Prevention
(CSGADP) RFA. Broad area of interest: Pathways, mechanisms, and means best suited to
practical preventive interventions. Specific research topic: Identification and elucidation of
cellular and immune pathways that may provide targets for preventive interventions.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.3389/fimmu.2020.01922
发表时间:
2020
期刊:
Frontiers in immunology
影响因子:
7.3
作者:
[Harms RZ, Ostlund KR, Cabrera MS, Edwards E, Fisher M, Sarvetnick N]
通讯作者:
Sarvetnick N
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
-
批准号:10230365
-
项目类别:
-
资助金额:$6.31万
-
财政年份:2020
-
负责人:Nora E Sarvetnick
-
依托单位:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
-
批准号:9917451
-
项目类别:
-
资助金额:$72.46万
-
财政年份:2019
-
负责人:Nora E Sarvetnick
-
依托单位:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
-
批准号:10468752
-
项目类别:
-
资助金额:$72.87万
-
财政年份:2019
-
负责人:Nora E Sarvetnick
-
依托单位:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
-
批准号:10021542
-
项目类别:
-
资助金额:$73.35万
-
财政年份:2019
-
负责人:Nora E Sarvetnick
-
依托单位:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
-
批准号:10239082
-
项目类别:
-
资助金额:$72.87万
-
财政年份:2019
-
负责人:Nora E Sarvetnick
-
依托单位:
Cytokine receptor populations in human autoimmune diabetes
-
批准号:8499253
-
项目类别:
-
资助金额:$55.65万
-
财政年份:2012
-
负责人:Nora E Sarvetnick
-
依托单位:
Cytokine receptor populations in human autoimmune diabetes
-
批准号:8681355
-
项目类别:
-
资助金额:$56.43万
-
财政年份:2012
-
负责人:Nora E Sarvetnick
-
依托单位:
Cytokine receptor populations in human autoimmune diabetes
-
批准号:9096009
-
项目类别:
-
资助金额:$48.64万
-
财政年份:2012
-
负责人:Nora E Sarvetnick
-
依托单位:
Cytokine receptor populations in human autoimmune diabetes
-
批准号:8374068
-
项目类别:
-
资助金额:$51.56万
-
财政年份:2012
-
负责人:Nora E Sarvetnick
-
依托单位:
Are IL-18 receptor-bearing CD8 T cells pathogenic in human Type 1 diabetes?
-
批准号:8313163
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2011
-
负责人:Nora E Sarvetnick
-
依托单位:
Mechanistic insights into B7 co-stimulation
-
批准号:7418198
-
项目类别:
-
资助金额:$19.18万
-
财政年份:2006
-
负责人:Nora E Sarvetnick
-
依托单位:
Mechanistic insights into B7 co-stimulation
-
批准号:7628576
-
项目类别:
-
资助金额:$51.9万
-
财政年份:2006
-
负责人:Nora E Sarvetnick
-
依托单位:
Mechanistic insights into B7 co-stimulation
-
批准号:7869314
-
项目类别:
-
资助金额:$35.01万
-
财政年份:2006
-
负责人:Nora E Sarvetnick
-
依托单位:
Mechanistic insights into B7Co-stimulation
-
批准号:7150088
-
项目类别:
-
资助金额:$46.48万
-
财政年份:2006
-
负责人:Nora E Sarvetnick
-
依托单位:
Mechanistic insights into B7 co-stimulation
-
批准号:7742488
-
项目类别:
-
资助金额:$20.33万
-
财政年份:2006
-
负责人:Nora E Sarvetnick
-
依托单位:
Mechanistic insights into B7 co-stimulation
-
批准号:7232759
-
项目类别:
-
资助金额:$45.13万
-
财政年份:2006
-
负责人:Nora E Sarvetnick
-
依托单位:
Immunoregulation of Flavivirus Infection
-
批准号:7140429
-
项目类别:
-
资助金额:$18.15万
-
财政年份:2005
-
负责人:Nora E Sarvetnick
-
依托单位:
Functional Tolerance to Islet Allografts
-
批准号:6967077
-
项目类别:
-
资助金额:$32.53万
-
财政年份:2005
-
负责人:Nora E Sarvetnick
-
依托单位:
Immunoregulation of Flavivirus Infection
-
批准号:6966726
-
项目类别:
-
资助金额:$32.53万
-
财政年份:2005
-
负责人:Nora E Sarvetnick
-
依托单位:
Functional Tolerance to Islet Allografts
-
批准号:7140441
-
项目类别:
-
资助金额:$18.15万
-
财政年份:2005
-
负责人:Nora E Sarvetnick
-
依托单位:
海外基金